Patents Assigned to Arch Oncology, Inc.
-
Patent number: 11692035Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: December 4, 2019Date of Patent: July 4, 2023Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Patent number: 11292834Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: GrantFiled: February 28, 2019Date of Patent: April 5, 2022Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang, Robert W. Karr
-
Patent number: 11202828Abstract: Anti-SIRP? monoclonal antibodies (anti-SIRP? mAbs), including multispecific SIRP? antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRP? mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRP? monoclonal antibodies.Type: GrantFiled: November 13, 2019Date of Patent: December 21, 2021Assignee: Arch Oncology, Inc.Inventors: Robyn Puro, Ronald R. Hiebsch, Benjamin J. Capoccia, Gabriela Andrejeva, Juan C. Almagro, Daniel S. Pereira
-
Patent number: 10844124Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: February 8, 2019Date of Patent: November 24, 2020Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Patent number: 10676524Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.Type: GrantFiled: October 3, 2017Date of Patent: June 9, 2020Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Patent number: 10669336Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.Type: GrantFiled: October 3, 2017Date of Patent: June 2, 2020Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Patent number: 10259873Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: GrantFiled: November 8, 2016Date of Patent: April 16, 2019Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Patent number: 10239945Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: November 21, 2017Date of Patent: March 26, 2019Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr